Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering

Odyssey Therapeutics, Inc. has announced the pricing of its upsized initial public offering (IPO), which will involve the sale of 15,500,000 shares of common stock at a price of $18.00 per share, aiming for gross proceeds of approximately $304 million. The offering is set to begin trading on the Nasdaq Capital Market under the ticker symbol "ODTX" starting May 8, 2026, with the expected closing date around May 11, 2026. Additionally, the underwriters have been granted a 30-day option to purchase up to 2,325,000 additional shares.

Founded in 2021, Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune and inflammatory diseases. The company aims to revolutionize treatment standards by creating medicines that precisely address disease pathology. Odyssey's portfolio consists of internally developed drug candidates that have advanced through various clinical milestones, showcasing the company's commitment to addressing significant unmet medical needs in the biopharmaceutical sector.

The concurrent private placement of 1,388,889 shares to an affiliate of TPG Life Sciences Innovations at the IPO price further strengthens Odyssey's financial position. This strategic partnership with TPG Life Sciences, a prominent investor in the life sciences sector, aligns with Odyssey's goal of advancing its innovative therapies. The capital raised from both the IPO and the private placement is expected to support the ongoing development of Odyssey's product pipeline, which is designed to induce deep and durable remission in patients suffering from chronic inflammatory conditions.

The biopharmaceutical sector is currently experiencing heightened interest from investors, driven by advancements in drug development and an increasing focus on precision medicine. Odyssey's IPO comes at a time when public market conditions are becoming more favorable for biotech companies, allowing them to capitalize on investor enthusiasm for innovative therapies. The successful pricing of this IPO could signal a resurgence in public offerings within the biopharmaceutical space, potentially encouraging other companies to pursue similar paths.

In conclusion, Odyssey Therapeutics' IPO represents a significant milestone for the company as it seeks to leverage public capital to further its mission of transforming care for patients with autoimmune and inflammatory diseases. As the market for biopharmaceutical innovations continues to evolve, Odyssey's successful entry into the public sphere may pave the way for increased investment and development in this critical sector, fostering a landscape where novel therapies can thrive and improve patient outcomes.